文献速递产科生殖医学

亚临床甲状腺功能减退与甲状腺自身免疫在复发性流产中的系统综述与荟萃分析

Subclinical hypothyroidism and thyroid autoimmunity in recurrent pregnancy loss: a systematic review and meta-analysis.
PubMed 文献 · Fertil Steril · 2020-01-01

该系统综述与荟萃分析评估复发性流产(RPL)与甲状腺功能减退及甲状腺自身免疫的关联,并分析左甲状腺素治疗的效果。共纳入多项观察性研究和干预性研究,结果显示RPL与甲状腺自身免疫显著相关(OR 1.94,95%CI 1.43-2.64),但与亚临床甲状腺功能减退无显著关联(患病率12.9%,95%CI 0%-35.2%)。左甲状腺素治疗未改善后续活产率,无论是否存在甲状腺抗体。

要点

  • RPL与甲状腺自身免疫显著相关,OR 1.94(95%CI 1.43-2.64)。
  • 亚临床甲状腺功能减退在RPL中患病率12.9%(95%CI 0%-35.2%),但与RPL无显著关联。
  • 左甲状腺素未改善RPL女性后续活产率,无论是否存在甲状腺抗体。

核心结论

  • 基于有限的观察性研究,RPL与亚临床甲状腺功能减退无关联,左甲状腺素不改善后续妊娠结局。
  • RPL与甲状腺自身免疫存在关联,但左甲状腺素不改善后续妊娠结局。
  • RPL女性应筛查/治疗显性甲状腺疾病,但不支持筛查甲状腺自身免疫。
  • 目前无法对亚临床甲状腺功能减退的治疗提出推荐,急需前瞻性随机研究。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、EMBASE、Web of Science和CENTRAL数据库。
  • 纳入干预性研究和观察性研究,对象为RPL女性伴显性或亚临床甲状腺功能减退和/或甲状腺自身免疫。

主要发现

  • 两项干预性研究显示左甲状腺素未改善亚临床甲状腺功能减退女性(伴或不伴甲状腺抗体)的后续活产率。
  • 五项研究的荟萃分析显示RPL中亚临床甲状腺功能减退患病率为12.9%(95%CI 0%-35.2%)。
  • 17项研究的荟萃分析显示RPL与甲状腺自身免疫显著相关(OR 1.94,95%CI 1.43-2.64)。
  • 一项随机研究提示左甲状腺素对甲状腺自身免疫的甲状腺功能正常女性无获益。

关键数值与推荐

  • RPL与甲状腺自身免疫的关联:OR 1.94(95%CI 1.43-2.64)。
  • RPL中亚临床甲状腺功能减退患病率:12.9%(95%CI 0%-35.2%)。
  • 左甲状腺素未改善亚临床甲状腺功能减退女性(伴或不伴甲状腺抗体)的后续活产率。
  • 左甲状腺素对甲状腺自身免疫的甲状腺功能正常女性无获益。

临床怎么用

  • RPL女性应筛查和治疗显性甲状腺疾病。
  • 不支持对RPL女性常规筛查甲状腺自身免疫。
  • 目前无法对亚临床甲状腺功能减退的治疗提出推荐。

局限性

  • 基于有限的观察性研究。
  • 需要进一步随机研究。
  • 亚临床甲状腺功能减退的治疗推荐无法做出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether overt/subclinical hypothyroidism and/or thyroid autoimmunity is associated with recurrent pregnancy loss (RPL) and whether treatment improves outcomes. DESIGN: Systematic review and meta-analysis. SETTING: University obstetrics and gynecology departments. PATIENT(S): Women with RPL and overt/subclinical hypothyroidism, and/or thyroid autoimmunity. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Associations between RPL and overt/subclinical hypothyroidism and/or thyroid autoimmunity and any effects of treatment. RESULT(S): After our review of articles from PubMed, EMBASE, Web of Science, and CENTRAL, we found two interventional studies in which levothyroxine did not improve the subsequent live-birth rate in women with subclinical hypothyroidism with or without thyroid antibodies. A meta-analysis of five studies revealed the prevalence of subclinical hypothyroidism in RPL to be 12.9% (95% confidence interval [CI], 0%-35.2%). A meta-analysis of 17 studies revealed a statistically significant association between RPL and thyroid autoimmunity (odds ratio 1.94; 95% CI, 1.43-2.64). However, a randomized study suggested that levothyroxine does not benefit euthyroid women with thyroid autoimmunity. CONCLUSION(S): Based on the limited observational studies available, no association exists between RPL and subclinical hypothyroidism, nor does levothyroxine improve subsequent pregnancy outcomes. An association exists between RPL and thyroid autoimmunity, but levothyroxine does not improve subsequent pregnancy outcomes. Women with RPL should be screened/treated for overt thyroid disease but not thyroid autoimmunity. Thyroid antibody screening is not supported by the published studies, and further randomized studies are needed. No recommendation regarding the treatment of subclinical hypothyroidism can be made at this time; prospective and randomized studies are urgently needed.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Dong AC, Morgan J, Kane M, et al. Subclinical hypothyroidism and thyroid autoimmunity in recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril. 2020. PMID: 32192591. doi:10.1016/j.fertnstert.2019.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。